Patents by Inventor Samuel Agresta

Samuel Agresta has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF TREATING METASTATIC BREAST CANCER WITH TRASTUZUMAB-MCC-DM1
    Publication number: 20200069694
    Abstract: Methods of treating patients having metastatic or unresectable locally advanced HER2 positive cancer, e.g., breast cancer, with the antibody-drug conjugate trastuzumab-MCC-DM1 are provided, wherein the patients have received extensive prior treatment, e.g., with an anthracycline, a taxane, capecitabine, lapatinib, and trastuzumab.
    Type: Application
    Filed: November 1, 2019
    Publication date: March 5, 2020
    Applicant: GENENTECH, INC.
    Inventors: Samuel Agresta, Barbara Klencke
  • Compositions and methods for non-invasive imaging
    Patent number: 9968694
    Abstract: The present invention relates to a novel composition useful in targeted diagnostic and/or therapy of a target site, such as cancerous tissue. The composition and methods disclosed herein find particular use in diagnosing and imaging cancerous tissue. The present invention provides a new diagnostic tool for the utilization of positron emission tomography (PET) imaging technique.
    Type: Grant
    Filed: November 1, 2016
    Date of Patent: May 15, 2018
    Assignee: Merrimack Pharmaceuticals, Inc.
    Inventors: Daryl C. Drummond, Dmitri B. Kirpotin, Thomas Wickham, Bart S. Hendriks, Samuel Agresta, Helen Lee, Daniel F. Gaddy
  • METHODS OF TREATING METASTATIC BREAST CANCER WITH TRASTUZUMAB-MCC-DM1
    Publication number: 20170202973
    Abstract: Methods of treating patients having metastatic or unresectable locally advanced HER2 positive cancer, e.g., breast cancer, with the antibody-drug conjugate trastuzumab-MCC-DM1 are provided, wherein the patients have received extensive prior treatment, e.g., with an anthracycline, a taxane, capecitabine, lapatinib, and trastuzumab.
    Type: Application
    Filed: March 29, 2017
    Publication date: July 20, 2017
    Inventors: Samuel Agresta, Barbara Klencke
  • Compositions and Methods for Non-Invasive Imaging
    Publication number: 20170112950
    Abstract: The present invention relates to a novel composition useful in targeted diagnostic and/or therapy of a target site, such as cancerous tissue. The composition and methods disclosed herein find particular use in diagnosing and imaging cancerous tissue. The present invention provides a new diagnostic tool for the utilization of positron emission tomography (PET) imaging technique.
    Type: Application
    Filed: November 1, 2016
    Publication date: April 27, 2017
    Inventors: DARYL C. DRUMMOND, DMITRI B. KlRPOTIN, THOMAS WICKHAM, BART S. HENDRIKS, SAMUEL AGRESTA, HELEN LEE, DANIEL F. GADDY
  • Compositions and methods for non-invasive imaging
    Patent number: 9511155
    Abstract: The present invention relates to a novel composition useful in targeted diagnostic and/or therapy of a target site, such as cancerous tissue. The composition and methods disclosed herein find particular use in diagnosing and imaging cancerous tissue. The present invention provides a new diagnostic tool for the utilization of positron emission tomography (PET) imaging technique.
    Type: Grant
    Filed: April 17, 2013
    Date of Patent: December 6, 2016
    Assignee: MERRIMACK PHARMACEUTICALS, INC.
    Inventors: Daryl C. Drummond, Dmitri B. Kirpotin, Thomas Wickham, Bart S. Hendriks, Samuel Agresta, Helen Lee, Daniel F. Gaddy
  • METHODS OF TREATING METASTATIC BREAST CANCER WITH TRASTUZUMAB-MCC-DM1
    Publication number: 20150265723
    Abstract: Methods of treating patients having metastatic or unresectable locally advanced HER2 positive cancer, e.g., breast cancer, with the antibody-drug conjugate trastuzumab-MCC-DM1 are provided, wherein the patients have received extensive prior treatment, e.g., with an anthracycline, a taxane, capecitabine, lapatinib, and trastuzumab.
    Type: Application
    Filed: June 1, 2015
    Publication date: September 24, 2015
    Inventors: Samuel Agresta, Barbara Klencke
  • COMPOSITIONS AND METHODS FOR NON-INVASIVE IMAGING
    Publication number: 20150093328
    Abstract: The present invention relates to a novel composition useful in targeted diagnostic and/or therapy of a target site, such as cancerous tissue. The composition and methods disclosed herein find particular use in diagnosing and imaging cancerous tissue. The present invention provides a new diagnostic tool for the utilization of positron emission tomography (PET) imaging technique.
    Type: Application
    Filed: April 17, 2013
    Publication date: April 2, 2015
    Applicant: MERRIMACK PHARMACEUTICALS, INC.
    Inventors: Daryl C. Drummond, Dmitri B. Kirpotin, Thomas Wickham, Bart S. Hendricks, Samuel Agresta, Helen Lee
  • METHODS OF TREATING METASTATIC BREAST CANCER WITH TRASTUZUMAB-MCC-DM1
    Publication number: 20110165155
    Abstract: Methods of treating patients having metastatic or unresectable locally advanced HER2 positive cancer, e.g., breast cancer, with the antibody-drug conjugate trastuzumab-MCC-DM1 are provided, wherein the patients have received extensive prior treatment, e.g., with an anthracycline, a taxane, capecitabine, lapatinib, and trastuzumab.
    Type: Application
    Filed: December 3, 2010
    Publication date: July 7, 2011
    Applicant: Genentech, Inc.
    Inventors: Samuel Agresta, Barbara Klencke